title: Multiepitope fusion antigen induces broadly protective antibodies that prevent adherence of Escherichia coli strains expressing colonization factor antigen I (CFA/I), CFA/II, and CFA/IV.
abstract: Diarrhea is the second leading cause of death in children younger than 5 years and continues to be a major threat to global health. Enterotoxigenic Escherichia coli (ETEC) strains are the most common bacteria causing diarrhea in developing countries. ETEC strains are able to attach to host small intestinal epithelial cells by using bacterial colonization factor antigen (CFA) adhesins. This attachment helps to initiate the diarrheal disease. Vaccines that induce antiadhesin immunity to block adherence of ETEC strains that express immunologically heterogeneous CFA adhesins are expected to protect against ETEC diarrhea. In this study, we created a CFA multiepitope fusion antigen (MEFA) carrying representative epitopes of CFA/I, CFA/II (CS1, CS2, and CS3), and CFA/IV (CS4, CS5, and CS6), examined its immunogenicity in mice, and assessed the potential of this MEFA as an antiadhesin vaccine against ETEC. Mice intraperitoneally immunized with this CFA MEFA exhibited no adverse effects and developed immune responses to CFA/I, CFA/II, and CFA/IV adhesins. Moreover, after incubation with serum of the immunized mice, ETEC or E. coli strains expressing CFA/I, CFA/II, or CFA/IV adhesins were significantly inhibited in adherence to Caco-2 cells. Our results indicated this CFA MEFA elicited antibodies that not only cross-reacted to CFA/I, CFA/II and CFA/IV adhesins but also broadly inhibited adherence of E. coli strains expressing these seven adhesins and suggested that this CFA MEFA could be a candidate to induce broad-spectrum antiadhesin protection against ETEC diarrhea. Additionally, this antigen construction approach (creating an MEFA) may be generally used in vaccine development against heterogenic pathogens.
authors.affiliation: Veterinary and Biomedical Sciences Department, The Center for Infectious Disease Research and Vaccinology, South Dakota State University, Brookings, South Dakota, USA.
authors.forename: Xiaosai
authors.initials: X
authors.lastname: Ruan
authors.forename: David E
authors.initials: DE
authors.lastname: Knudsen
authors.forename: Katie M
authors.initials: KM
authors.lastname: Wollenberg
authors.forename: David A
authors.initials: DA
authors.lastname: Sack
authors.forename: Weiping
authors.initials: W
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001422:Bacterial Adhesion / Q000187:drug effects; D018938:Caco-2 Cells; D003087:Colicins; D003967:Diarrhea / Q000276:immunology / Q000517:prevention & control; D054307:Enterotoxigenic Escherichia coli / Q000235:genetics / Q000276:immunology*; D004847:Epithelial Cells / Q000382:microbiology; D000939:Epitopes / Q000235:genetics / Q000276:immunology*; D004927:Escherichia coli Infections / Q000276:immunology / Q000517:prevention & control*; D022361:Escherichia coli Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D005260:Female; D036781:Fimbriae Proteins / Q000235:genetics / Q000276:immunology*; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D003087:Colicins; D000939:Epitopes; D022361:Escherichia coli Vaccines; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; C096880:colicin 5 protein, E coli; C022924:colonization factor antigens; D036781:Fimbriae Proteins